Antifungal Prophylaxis Regimens in Liver Transplant Found Equal

This article originally appeared here.
Share this content:
Antifungal Prophylaxis Regimens in Liver Transplant Found Equal
Antifungal Prophylaxis Regimens in Liver Transplant Found Equal

MONDAY, Dec. 8, 2014 (HealthDay News) -- Antifungal prophylaxis is associated with reductions in invasive fungal infections (IFIs) in liver transplant recipients, according to research published in the December issue of the American Journal of Transplantation.

J.D.W. Evans, from Cambridge University in the United Kingdom, and colleagues conducted a comprehensive literature search and identified randomized controlled trials comparing regimens for antifungal prophylaxis in liver transplant recipients. Data were included from 14 studies, with comparisons of fluconazole, liposomal amphotericin B (L-AmB), itraconazole, micafungin, and placebo.

The researchers found that the rate of proven IFI, suspected or proven IFI, and mortality due to IFI were reduced with antifungal prophylaxis (odds ratios, 0.37, 0.40, and 0.32, respectively) compared to placebo. There was no significant effect observed for all-cause mortality. No significant difference was seen in the risk of adverse events requiring cessation of prophylaxis (odds ratio, 1.11; 95 percent confidence interval, 0.48 to 2.55; P = 0.81). In the network meta-analysis, similar reductions were seen in the rate of IFI for fluconazole and L-AmB versus placebo (odds ratios, 0.21 and 0.21, respectively).

"Routine prophylaxis with fluconazole or L-AmB reduces the incidence of IFI following liver transplantation, and the available evidence suggests that the two are equivalent in efficacy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »